50573-74-5

Usage

Uses

Used in Pharmaceutical Industry:
2-Amino-6-nitrobenzoic acid is used as a chemical intermediate for the synthesis of various pharmaceutical compounds, including antibiotics and anti-inflammatory drugs, due to its unique chemical structure and reactivity.
Used in Environmental Research:
2-Amino-6-nitrobenzoic acid is utilized as a biomarker in environmental studies to assess the presence and impact of genotoxic compounds, such as dinitrotoluene, on ecosystems and human health.
Used in Chemical Synthesis:
2-Amino-6-nitrobenzoic acid is employed as a building block in the synthesis of various organic compounds, including dyes, pigments, and polymers, owing to its versatile functional groups and chemical properties.

InChI:InChI=1/C7H6N2O4/c8-4-2-1-3-5(9(12)13)6(4)7(10)11/h1-3H,8H2,(H,10,11)

Upstream product

• 641-70-3 3-nitrophthalic acid anhydride 
• 606-20-2 2,6-dinitrotoluene 
• 71-43-2 benzene 
• 20829-97-4 5-nitroisatonic anhydride 
• 7732-18-5 water 
• 603-62-3 4-nitro-1H-isoindole-1,3(2H)-dione 
• 96385-50-1 3-nitrophthalamide 
• 675575-44-7 2-ethoxycarbonylamino-6-nitro-benzoic acid 
• 65911-46-8 2-carbamoyl-6-nitrobenzoic acid 
• 603-11-2 3-nitrophthalic acid 
• 603-12-3 2,6-dinitrobenzoic acid 
• 872266-38-1 2-azidocarbonyl-6-nitro-benzoic acid 
• 77326-45-5 2-carbamoyl-3-nitrobenzoic acid 

Downstream Products

• 554-84-7 meta-nitrophenol 
• 89641-04-3 2-iodo-6-nitrobenzoic acid 
• 102000-59-9 2,6-diaminobenzoic acid 
• 57113-89-0 2-amino-6-nitrobenzoic acid methylester 
• 99-09-2 3-nitro-aniline 
• 104898-55-7 methyl 2-chlorosulfonyl-6-nitrobenzoate 
• 106324-19-0 Methyl 2--6-nitrobenzoate 
• 106324-20-3 N-(2-Hydroxyethyl) 2-(2-hydroxyethylamino)sulfonyl-6-nitrobenzoate 
• 6943-17-5 6-nitro-4-oxoquinazoline 
• 1202679-11-5 N₁-cyclopropylmethyl-2-amino-6-nitro-benzamide 
• 1191076-41-1 C₇H₄N₄O₄ 
• 99768-67-9 5-nitro-3H-quinazolin-4-one 
• 1268696-09-8 C₁₉H₁₉N₃O₆ 
• 1268696-13-4 C₁₉H₁₉N₃O₆ 

Relevant academic research and scientific papers

Vicarious nucleophilic substitution: A dramatically shortened synthesis of 2-amino-6-nitrobenzoic acid labelled with carbon-14

Literature preparations of 2-amino-6-nitrobenzoic acid are usually based on phthalic anhydride. In order to make [benzene-14C(U)]-2-amino-6- nitrobenzoic acid, [benzene-14C(U)]-phthalic anhydride has to be prepared in multiple steps from [14C(U)]-benzene, resulting in an unacceptably lengthy 14-step synthesis. We have been able to develop a completely different method of synthesis, producing [benzene- 14C(U)]-2-amino-6-nitrobenzoic acid from [14C(U)]-benzene in just four steps with an overall radiochemical yield of 32%.

SOLID FORMS OF 3-(5-AMINO-2-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE, AND THEIR PHARMACEUTICAL COMPOSITIONS AND USES

Solid forms comprising 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)- piperidine-2,6-dione, compositions comprising the solid forms, methods of making the solid forms and methods of their uses are disclosed.

METHODS FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIA AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO IMMUNOMODULATORY THERAPIES

A method of identifying a subject having chronic lymphocytic leukemia (CLL) who is likely to be responsive to a treatment compound, comprising obtaining a first sample and a second sample from the subject having CLL; administering 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione (Compound A) to the first sample and administering lenalidomide to the second sample; determining the level of a biomarker in the first sample and determining the level of the biomarker in the second sample; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the first sample is different from the level of the biomarker in the second sample.

METHODS FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA AND THE USE OF BIOMARKERS AS A PREDICTOR OF RESPONSIVENESS TO DRUGS

In one aspect, provided herein are methods for predicting the responsiveness of DLBCL patients to treatment with lenolidomide or Compound A; or a stereoisomer thereof; or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate thereof; or a polymorph thereof utilizing biomarkers or classfiers that correlate with responsiveness to one of these drugs. In another aspect, provided herein are methods for treating a DLBCL patient determined to be responsive to treatment with lenolidomide or Compound A; or a stereoisomer thereof; or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate thereof; or a polymorph thereof utilizing biomarkers or classifiers (or output thereof) that correlate with responsiveness to one of these drugs.

CYCLING THERAPY USING 3-(5-AMINO-2-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE

Provided herein are methods of treating, preventing and/or managing cancer, including lymphoma, which comprise administering to a patient 3-(5-amino-2-methyl-4- oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in a cyclic therapy regimen.

COMPOSITIONS AND METHODS FOR INDUCING CONFORMATIONAL CHANGES IN CEREBLON AND OTHER E3 UBIQUITIN LIGASES

Provided herein are compositions, therapeutic methods, screening methods, computational methods and biomarkers based upon the elucidation of the interaction among cereblon, its substrates and certain compounds or agents, including small molecules, peptides, and proteins.

Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor

Uses of the protein cereblon as a predictor of clinical sensitivity to cancer, inflammatory diseases, and patient response to drug treatment.

METHODS FOR TREATING SOLID TUMORS AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO IMMUNOMODULATORY THERAPIES

A method of identifying a subject having a solid tumor who is likely to be responsive to a treatment compound, comprising: administering the treatment compound to a subject having the solid tumor; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject, and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker.

COMPOSITIONS AND METHODS FOR INDUCING CONFORMATIONAL CHANGES IN CEREBLON OTHER E3 UBIQUITIN LIGASES

Provided herein are compositions, therapeutic methods, screening methods, computational methods and biomarkers based upon the elucidation of the interaction among cerebloR, its substrates and certain compounds or agents, including small molecules, peptides, and proteins.

Zn-Catalyzed Enantio- and Diastereoselective Formal [4 + 2] Cycloaddition Involving Two Electron-Deficient Partners: Asymmetric Synthesis of Piperidines from 1-Azadienes and Nitro-Alkenes

We report a catalytic asymmetric synthesis of piperidines through [4 + 2] cycloaddition of 1-azadienes and nitro-alkenes. The reaction uses earth abundant Zn as catalyst and is highly diastereo- and regioselective. A novel BOPA ligand (F-BOPA) confers high reactivity and enantioselectivity in the process. The presence of ortho substitution on the arenes adjacent to the bis(oxazolines) was found to be particularly impactful, due to limiting the undesired coordination of 1-azadiene to the Lewis acid and thus allowing the reaction to be carried out at lower temperature. A series of secondary kinetic isotope effect studies using a range of ligands implicates a stepwise mechanism for the transformation, involving an initial Michael-type addition of the imine to the nitro-alkene followed by a cyclization event. The stepwise mechanism obviates the electronic requirement inherent to a concerted mechanism, explaining the successful cycloaddition between two electron-deficient partners. (Chemical Equation Presented).